Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic DMMR Colorectal Cancers

Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.